Oliver Lagore Vanvalin Investment Group Has $139,000 Stock Position in Amgen Inc. (NASDAQ:AMGN)

Oliver Lagore Vanvalin Investment Group lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 8.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 482 shares of the medical research company’s stock after purchasing an additional 39 shares during the quarter. Oliver Lagore Vanvalin Investment Group’s holdings in Amgen were worth $139,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of AMGN. Moneta Group Investment Advisors LLC boosted its stake in Amgen by 83,875.6% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock valued at $1,980,571,000 after buying an additional 7,532,031 shares in the last quarter. Norges Bank acquired a new stake in Amgen in the fourth quarter valued at about $1,351,778,000. Price T Rowe Associates Inc. MD boosted its stake in Amgen by 158.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,950,013 shares of the medical research company’s stock valued at $774,791,000 after buying an additional 1,806,456 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in Amgen in the fourth quarter valued at about $4,589,900,000. Finally, Morgan Stanley boosted its stake in Amgen by 12.9% in the fourth quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock valued at $3,493,471,000 after buying an additional 1,523,665 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AMGN has been the subject of several research reports. The Goldman Sachs Group increased their target price on Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. Oppenheimer reiterated an “outperform” rating and issued a $350.00 target price on shares of Amgen in a research report on Thursday, February 1st. Leerink Partnrs downgraded Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Daiwa Capital Markets upgraded Amgen from a “neutral” rating to a “buy” rating and increased their target price for the company from $264.00 to $320.00 in a research report on Thursday, December 21st. Finally, UBS Group dropped their target price on Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a research report on Wednesday. Ten equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $296.95.

Amgen Price Performance

Shares of AMGN opened at $262.75 on Friday. The business has a 50-day moving average of $277.34 and a 200-day moving average of $281.24. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $329.72. The company has a market capitalization of $140.81 billion, a price-to-earnings ratio of 21.04, a price-to-earnings-growth ratio of 2.46 and a beta of 0.58. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping the consensus estimate of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. During the same quarter last year, the firm posted $4.09 earnings per share. The firm’s revenue was up 19.8% on a year-over-year basis. As a group, equities research analysts anticipate that Amgen Inc. will post 19.45 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a yield of 3.43%. Amgen’s dividend payout ratio is currently 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.